TCM
VRTX icon

TruNorth Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

TruNorth Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-200
Closed -$78.3K – 381
2025
Q3 		$78.3K Hold
200
– – 0.02% 143
2025
Q2 		$89K Hold
200
– – 0.02% 123
2025
Q1 		$97K Hold
200
– – 0.02% 143
2024
Q4 		$80.5K Hold
200
– – 0.02% 116
2024
Q3 		$93K Hold
200
– – 0.03% 100
2024
Q2 		$93.7K Buy
+200
New +$86.8K 0.03% 91

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

TruNorth Capital Management's VRTX Position: Q4 2025 in Review

TruNorth Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 200 shares — an estimated $78.3K sold.

TruNorth Capital Management first reported a position in VRTX in Q2 2024 and held it in 6 quarters. The position peaked at $97K in Q1 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • TruNorth Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • TruNorth Capital Management sold 200 Vertex Pharmaceuticals shares in Q4 2025, an estimated $78.3K.
  • TruNorth Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 6 quarters.
  • TruNorth Capital Management's Vertex Pharmaceuticals position peaked at $97K in Q1 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on TruNorth Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.